Inactive Instrument

Tryp Therapeutics Inc. Canadian Securities Exchange

Equities

TRYP

CA89854F1062

Biotechnology & Medical Research

Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022

January 26, 2023 at 03:59 am IST

Tryp Therapeutics Inc. reported earnings results for the first quarter ended November 30, 2022. For the first quarter, the company reported net loss was CAD 1.63 million compared to CAD 3 million a year ago.

Latest news about Tryp Therapeutics Inc.

Tryptamine Therapeutics Begins to Trade on ASX; Shares Surge 118%	29/05	MT
Tryptamine Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	29/04	CI
3,043,860 Common Shares of Tryptamine Therapeutics Limited are subject to a Lock-Up Agreement Ending on 18-DEC-2023.	18/12	CI
3,043,860 Common Shares of Tryptamine Therapeutics Limited are subject to a Lock-Up Agreement Ending on 20-JUN-2023.	20/23/20	CI

Chart Tryp Therapeutics Inc.

Duration

Period

More charts

Company Profile

Tryptamine Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on the development of an advanced and scalable intravenous-infused psilocin formulation, which can be used in conjunction with psychotherapy to address significant unmet medical needs. It is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. It intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin). Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The Company is engaged in pursuing Phase II clinical trials using its psilocybin and psilocin-based drug products for chronic pain and eating disorders. The Company's pipeline products include TRP-8803 and TRP-8802.

Sector

Biotechnology & Medical Research

Calendar

25/07/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research